top of page
Browse by category
Search
Pfizer to acquire Metsera and its next-generation obesity portfolio
Pfizer and Metsera have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical...
Pfizer to discontinue development oral GLP-1 receptor agonist Danuglipron
Pfizer has decided to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist,...
Flagship Pioneering, ProFound Therapeutics and Pfizer to identify novel first-in-class therapeutics for the treatment of obesity
Flagship Pioneering and ProFound Therapeutics have entered a collaboration to conduct foundational research to identify potential...
Pfizer’s twice-daily danuglipron formulation to be discontinued after high rates of GI complaints
Topline data from Pfizer’s Phase 2b clinical trial investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate,...
GLP-1-RA: Pfizer to continue danuglipron but discontinue lotiglipron
Pfizer will continue to progress its first full agonist oral glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate - danuglipron...
Browse by tag
bottom of page